MyOme Presents New Data at ASHG 2022 on an Ethnically-Inclusive Breast Cancer Risk Assessment

Addition of a cross-ancestry polygenic risk score to the standard of care clinical risk predictor tool improved breast cancer risk assessment across multiple ancestries

Excerpt from the Press Release:

MENLO PARK, Calif., Oct. 27, 2022 /PRNewswire/ — MyOme, a clinical whole genome platform analysis company, today announced new data on its cross-ancestry integrated risk score (caIRS) for breast cancer risk assessment that will be presented at the 2022 American Society of Human Genetics (ASHG) Annual Meeting in Los Angeles. In a study on more than 270,000 women across multiple ancestries, data showed that there was a significant increase in breast cancer risk assessment performance when a cross-ancestry polygenic risk score was integrated into the standard of care risk prediction tool.

“Polygenic risk scores- which aggregate the impact of many genetic variants with individually small effect sizes into a single measure- have shown increasing utility in many aspects of medicine with improvement of risk classification for breast cancer being a pivotal near-term example,” said Matthew Rabinowitz, PhD, co-founder and executive chairman of MyOme.

Key findings from the study include:

• caIRS was significantly correlated with odds of breast cancer across multiple ancestries including East Asian, South Asian, Hispanic, African American, Caucasian.
• caIRS outperformed Tyrer-Cuzick alone across multiple ancestries .
• Hispanic women showed the largest improvement in remaining lifetime breast cancer risk; 44% increase in odds ratio per unit standard deviation (increase from 1.31 to 1.88)

Click the button below to read the entire Press Release:

Continue Reading The Press Release